Analysis of global adverse drug reports reveals that mTOR inhibitors—drugs targeting a key longevity pathway—carry significant safety risks. Sirolimus showed a 132% increased risk of gastrointestinal hemorrhage and 67% higher likelihood of interstitial lung disease, while temsirolimus elevated pneumonia risk by 40% and sepsis by 36%. These findings illuminate a critical tension in longevity medicine. The mTOR pathway controls cellular aging, metabolism, and growth, making its inhibitors attractive for anti-aging interventions. Rapamycin analogues like sirolimus have shown promise in extending lifespan in animal studies and are increasingly used off-label for longevity purposes. However, this safety analysis suggests therapeutic doses carry substantial risks including life-threatening bleeding, lung inflammation, and severe infections due to immunosuppression. The data represents real-world clinical experience rather than controlled trials, providing valuable insights into actual usage patterns. For longevity enthusiasts considering mTOR inhibitors, these findings underscore the need for careful medical supervision and regular monitoring. The risk-benefit calculus may favor lower, intermittent dosing strategies that preserve longevity benefits while minimizing adverse events—an approach requiring more research to optimize.